ArticleThe New England journal of medicine2018
Durvalumab in Stage III Non-Small-Cell Lung Cancer.
Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05213312 (A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma
Who cites it
12 citing papers in PubMed.
- Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Advances in therapy · 2026Article
- Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.Nature medicine · 2024Article
- The role of chemoradiotherapy and immunotherapy in stage III NSCLC.Pathology oncology research : POR · 2024Review
- Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial).Journal of thoracic disease · 2023Article
- Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer.Respirology (Carlton, Vic.) · 2023Article
- Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.Current treatment options in oncology · 2021Review
- The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- Neoadjuvant treatment of stage IIIA-N2 inTranslational lung cancer research · 2021Review
- Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer.Journal of thoracic disease · 2020Article
- Review
- Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.Translational lung cancer research · 2019Article
- SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29490170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.